{"id":"NCT02453555","sponsor":"Boehringer Ingelheim","briefTitle":"Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus","officialTitle":"A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-14","primaryCompletion":"2016-08-26","completion":"2017-03-27","firstPosted":"2015-05-25","resultsPosted":"2019-02-15","lastUpdate":"2019-02-15"},"enrollment":275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Linagliptin","otherNames":["tablet"]},{"type":"DRUG","name":"Empagliflozin placebo + linagliptin placebo low dose","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + linagliptin low dose","otherNames":[]},{"type":"DRUG","name":"Linagliptin placebo","otherNames":[]},{"type":"DRUG","name":"Empagliflozin + linagliptin high dose","otherNames":[]},{"type":"DRUG","name":"Empa + lina highdose placebo","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"ACTIVE_COMPARATOR"},{"label":"Empagliflozin + linagliptin low dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin + linagliptin high dose","type":"EXPERIMENTAL"},{"label":"Linagliptin placebo","type":"PLACEBO_COMPARATOR"},{"label":"Empagliflozin + linagliptin high dose placebo","type":"PLACEBO_COMPARATOR"},{"label":"Empagliflozin + linagliptin low dose placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus","primaryOutcome":{"measure":"Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)","timeFrame":"Baseline and 24 week","effectByArm":[{"arm":"Empagliflozin 10 mg/Linagliptin 5 mg","deltaMin":-0.93,"sd":0.06},{"arm":"Linagliptin 5 mg + Placebo 10 mg","deltaMin":0.21,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["Japan"]},"refs":{"pmids":["29766636"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":182},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Asymptomatic bacteriuria","Blood ketone body increased"]}}